430 related articles for article (PubMed ID: 34218062)
1. Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
Farlow JL; Brenner JC; Lei YL; Chinn SB
Oral Oncol; 2021 Sep; 120():105420. PubMed ID: 34218062
[TBL] [Abstract][Full Text] [Related]
2. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Head and Neck Cancer.
Sim F; Leidner R; Bell RB
Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
5. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
[TBL] [Abstract][Full Text] [Related]
6. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
[TBL] [Abstract][Full Text] [Related]
7. Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature.
Hong Q; Ding S; Xing C; Mu Z
Medicine (Baltimore); 2024 Mar; 103(9):e37387. PubMed ID: 38428879
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment in head and neck cancers.
Chen SMY; Krinsky AL; Woolaver RA; Wang X; Chen Z; Wang JH
Mol Carcinog; 2020 Jul; 59(7):766-774. PubMed ID: 32017286
[TBL] [Abstract][Full Text] [Related]
9. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD; Liu ZZ; Liu YY; Fu YC; Lin LL; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():791621. PubMed ID: 35003112
[TBL] [Abstract][Full Text] [Related]
11. The biology of combination immunotherapy in recurrent metastatic head and neck cancer.
Yuan X; Yi M; Zhang W; Xu L; Chu Q; Luo S; Wu K
Int J Biochem Cell Biol; 2021 Jul; 136():106002. PubMed ID: 33962022
[TBL] [Abstract][Full Text] [Related]
12. The 5-Ws of immunotherapy in head and neck cancer.
Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
[TBL] [Abstract][Full Text] [Related]
13. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
Freiser ME; Serafini P; Weed DT
Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
[TBL] [Abstract][Full Text] [Related]
14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Head and Neck Squamous Cell Carcinoma.
Moskovitz J; Moy J; Ferris RL
Curr Oncol Rep; 2018 Mar; 20(2):22. PubMed ID: 29502288
[TBL] [Abstract][Full Text] [Related]
16. Immunology and Immunotherapy of Head and Neck Cancer.
Ferris RL
J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
[TBL] [Abstract][Full Text] [Related]
17. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.
Lin C; Chu Y; Zheng Y; Gu S; Hu Y; He J; Shen Z
Front Immunol; 2024; 15():1337129. PubMed ID: 38650924
[TBL] [Abstract][Full Text] [Related]
18. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
19. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
20. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.
Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P
Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
